In Cuba, 30 million doses of the Abdala vaccine have been produced to guarantee the immunization of the population over 19 years of age , which includes pregnant women, nursing mothers, people with transplants, adolescents and young people in terminal grades of the national education system, reported On its account on the social network Twitter this Saturday, September 25, the Center for Genetic Engineering and Biotechnology (CIGB), an institution that promotes the immunogen.
On the day of this Friday it was announced that the Ismaelillo trial with the Abdala vaccine in children from three to 18 years of age, carried out for almost three months in the city of Camagüey, was a success for Cuban science, in search of the authorization of the drug with a view to its application in the child population.
Abdala is the first vaccine developed and produced in Latin America and that managed to obtain emergency use by a regulatory authority , in this case by the Center for State Control of Medicines, Medical Equipment and Devices (CECMED). In its phase III clinical trial, the immunogen showed 92.28% efficacy against symptomatic disease, 100% efficacy in preventing severe systemic disease, and 100% in preventing death in the vaccinated group.
More than 4,862,000 Cubans have completed their immunisation schedule
At the end of September 23, 19,751,634 doses administered with the Cuban vaccines Soberana 02, Soberana Plus and Abdala have accumulated in the country , the Ministry of Public Health (Minsap) reported on its website.
According to the daily update offered by the Minsap on the vaccination strategy in the country, to date 8,815,520 people have received at least one dose of one of the Cuban vaccines Soberana 02, Soberana Plus and Abdala.
Of these they already have a second dose 6 062 414 people and a third dose 4 862 226 people. As a single dose of the Soberana Plus vaccine, 11,474 doses have been administered, said the Minsap.